ArticleCureus2025
Weekly Teriparatide Treatment Decreases Microdamage in Tibial Trabecular Bone of Ovariectomized Cynomolgus Monkeys.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background/purposeOsteoporosis is commonly treated with daily or weekly teriparatide, yet its impact on microdamage accumulation - a critical contributor to bone fragility - remains insufficiently evaluated in animal models. We evaluated the effects of weekly teriparatide on microdamage in tibial trabecular bone and examined its associations with bone mass, structure, turnover, and collagen cross-linking in ovariectomized (OVX) cynomolgus monkeys.
methodsSeventy-seven adult female cynomolgus monkeys were randomized into four groups (n = 18-20 each): sham-operated, OVX + vehicle, and OVX + weekly teriparatide at 1.2 μg/kg or 6.0 μg/kg. After 18 months, proximal tibiae and iliac crest specimens were harvested. Tibial trabecular sections were assessed for histomorphometry, microdamage (crack density, crack surface density), and collagen cross-linking. Iliac crest samples were analyzed for bone turnover indices.
resultsThe OVX group showed significantly higher microdamage accumulation compared to all other groups. Weekly teriparatide administration effectively prevented microdamage accumulation and improved collagen cross-link profile. Regression analysis revealed that reductions in microdamage correlated more strongly with decreased non-enzymatic pentosidine cross-links than with increases in trabecular bone volume or enzymatic cross-links.
conclusionsWeekly teriparatide administration attenuates tibial trabecular bone microdamage by restoring collagen cross-link balance, independent of bone mass gain. This suggests that teriparatide enhances bone quality and resistance to fracture via modulation of bone matrix integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.